SELLAS Life Sciences Group, Inc.

SLS ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2017 FY2016 FY2015 FY2014 FY2013 FY2012 FY2011 FY2010
Operating Activities
Net Income $-23.8M $-17.7M $-63.9M $-36.6M $-76.7M $-35.0M $-11.5M $-12.0M
Depreciation & Amortization $3.0K $107.0K $86.0K $286.0K $49.0K $163.0K $172.0K
Depreciation
Amortization $1.9M $440.0K $131.0K
Stock-Based Compensation $3.2M $354.0K $1.9M $4.7M $2.3M $1.4M $3.0M $4.4M
Net Cash from Operating Activities $-11.0M $-11.9M $-48.2M $-42.9M $-28.9M $-21.0M $-14.7M $-10.3M
Investing Activities
Capital Expenditures $6.0K $153.0K $57.0K $320.0K $53.0K $106.0K
Business Acquisitions $0 $0 $0 $15.1M $0
Net Cash from Investing Activities $12.2M $-85.0K $10.4M $-5.5M $-12.0M $-87.0K $14.0K $-106.0K
Financing Activities
Dividends Paid $0
Stock Repurchases $3.8M
Net Cash from Financing Activities $5.5M $16.5M $43.8M $24.3M $55.9M $42.4M $19.2M $11.6M
Net Change in Cash $-3.6M $4.6M $6.1M $-24.1M $15.0M $21.4M $4.5M $1.2M
Free Cash Flow $-11.9M $-48.3M $-42.9M $-29.2M $-14.7M $-10.4M
← Newer Page 2 of 2 Older →